iSchemaview, Inc. (operating as RapidAI)

Golden, CO All United States companies → — Founded 2011

Imaging AI Specialist

Neurology Neurosurgery Radiology

Neurology AI Radiology & Imaging AI

Series C — $103M

Claim this company

Products

Rapid MLS

iSchemaview, Inc. (operating as RapidAI)

Neurology AI

Rapid MLS by iSchemaview (RapidAI) is an AI-powered software that analyzes non-contrast CT scans to measure and visually display brain midline shifts, aiding in the assessment of intracranial hemorrhage and traumatic brain injury.

Not specified

See all 1 product →

About iSchemaview, Inc. (operating as RapidAI)

RapidAI, operating as iSchemaview, Inc., is a global leader in deep clinical artificial intelligence (AI) within the healthcare sector. The company provides an AI-enabled software platform designed to assist physicians in the rapid and accurate diagnosis and treatment of various life-threatening vascular and neurovascular conditions, including ischemic stroke, hemorrhagic stroke, cerebral aneurysms, and pulmonary embolisms. The platform utilizes AI to generate high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, MRI diffusion, and perfusion scans.

RapidAI’s solutions aim to enhance medical imaging and streamline stroke care workflows, offering tools for comprehensive assessment, aneurysm tracking, cardiac and vascular analysis, and optimized radiology processes. The Rapid Enterprise™ Platform integrates intelligence, workflow, and care teams across the health system, delivering real-time insights that foster confident decision-making and efficient resource allocation. The platform has analyzed over 10 million scans and is deployed in more than 2,200 hospitals across over 100 countries, with its clinically validated technology having played a significant role in expanding national stroke treatment guidelines.

Focus Areas

Neurovascular Cardiac & Vascular Radiology Life Sciences Ischemic Stroke Hemorrhagic Stroke Aneurysm Aortic Disease Pulmonary Embolism Trauma Clinical Decision Support Workflow Optimization Enterprise Imaging Care Coordination

Business Intelligence

Key Investors	Lennertz & Co., Vista Credit Partners, Cullom Capital, Listwin Ventures
Partnerships	Baptist Health, Health Holdings Company (Saudi Arabia), Amazon Web Services (AWS), Penumbra, Texas County Memorial Hospital (TCMH), Ambra Health, Samsung Neurologica, Mobile Heartbeat, Halo Health, Pulsara, Siemens Healthineers
Acquisitions	EndoVantage
Technology	Rapid Enterprise™ Platform, Deep Clinical AI, Rapid Edge Cloud (hybrid infrastructure, cloud-native with on-prem capabilities, Kubernetes), AI operating system, EMR integration, PACS integration, mobile app, Navigator Pro™
FDA Clearances	30+ cleared products (estimated)

What Physicians Need to Know

Neurovascular (Ischemic Stroke, Hemorrhagic Stroke, Aneurysm)

RapidAI offers advanced AI solutions for neurovascular conditions. For Ischemic Stroke, it includes Rapid ASPECTS for automated ASPECT scoring to determine thrombectomy eligibility and Rapid LVO for quick detection of large vessel occlusion, significantly expanding the treatment window. For Hemorrhagic Stroke, Rapid ICH 3.0 and Rapid Hyperdensity provide AI-driven bleed assessment for faster treatment decisions and can triage non-contrast CT cases for intracranial hemorrhage in under 3 minutes. Rapid Aneurysm is a comprehensive platform for managing aneurysms, aiding in risk identification, tracking changes, and guiding interventions.

Cardiac & Vascular (Aortic Disease, Pulmonary Embolism)

RapidAI has expanded its scope to include cardiac and vascular conditions. Rapid Aortic assists in identifying and tracking aortic patients. Rapid PE helps accelerate care pathways for Pulmonary Embolism by promptly notifying clinicians of suspected PE patients and streamlining workflows with AI results, source imaging, and clinical data.

Radiology

RapidAI seamlessly integrates into radiology workflows, offering solutions like Lumina by RapidAI for consistent, high-quality 3D reconstructions that expedite diagnosis across neurovascular cases. It automates image processing and analysis, providing easy-to-read, near real-time views of the brain, and lightens cognitive burden by reducing clicks and surfacing actionable AI findings within existing PACS, EHR, and reporting systems.

Trauma

RapidAI develops AI-driven imaging solutions for trauma, including the detection of subdural hematomas. Its hemorrhagic solutions, such as Rapid ICH 3.0 and Rapid Hyperdensity, also support clinicians in managing head trauma.

Clinical Decision Support & Workflow Optimization

The platform delivers contextual insights to reduce cognitive burden and enable confident decision-making. It automates image processing and analysis, providing near real-time views for faster, more accurate clinical decisions. Workflows are streamlined by integrating AI results, source imaging, clinical data, and communication tools into a single platform.

Enterprise Imaging & Care Coordination

RapidAI's Enterprise Platform connects intelligence, workflow, and multidisciplinary teams (ED, radiology, neurology, cardiology, intervention) across the health system. It facilitates secure mobile, desktop, and workstation tools for real-time communication and patient status tracking. Rapid Insights provides hospital-wide intelligence by monitoring utilization, study volume, performance metrics, and AI adoption.

Physician Tip

RapidAI stands out for physicians by offering: n* **Faster, More Accurate Diagnoses:** Provides critical information on stroke risk and detailed insights within minutes, enabling quicker and more confident clinical decisions.n* **Reduced Cognitive Burden and Burnout:** Automates image processing and analysis, delivering contextual insights and standardizing care, which assists less-experienced readers and reinforces expert decisions, thereby alleviating physician burnout.n* **Enhanced Collaboration and Care Coordination:** Facilitates seamless communication and image sharing among multidisciplinary care teams across various departments and hospitals, including convenient mobile access.n* **Improved Patient Outcomes:** By enabling faster treatment decisions and extending the treatment window for ischemic stroke, RapidAI directly contributes to better patient outcomes.n* **Reliable Second Opinion:** The AI acts as an intelligent assistant, supporting clinicians and radiologists in making crucial care decisions, particularly during demanding shifts.n* **Continuous Learning and Support:** Offers comprehensive education services, including self-paced courses and expert-led training (Rapid U), to help healthcare professionals enhance their skills and optimize workflows.

RapidAI's platform is designed for deep integration within existing hospital ecosystems. It integrates directly with PACS, EHR, worklists, and care-team tools, aiming to provide a unified experience rather than an additional layer to manage. The platform also supports a curated selection of vetted third-party algorithms to expand coverage across various service lines. Notably, it seamlessly integrates with communication platforms like Pulsara, allowing care teams to receive RapidAI results and access images directly within the Pulsara workflow for streamlined communication and review. RapidAI can also accommodate hospitals with unique integration requests or their own proprietary algorithms on its single platform.

At a glance

Founded 2011

HQ Golden, CO · United States

Team size 229

CEO Karim Karti

Funding Series C — $103M

FDA clearances 30+ (estimated)

Products 1

Products by iSchemaview, Inc. (operating as RapidAI)

1 product in the directory

Rapid MLS

iSchemaview, Inc. (operating as RapidAI)

Neurology AI

Not specified

What the Web Says

RapidAI, operating as iSchemaview, Inc., develops AI-driven imaging solutions primarily for stroke, trauma, and vascular conditions, aiming to expedite diagnosis and treatment decisions. The company's platform analyzes brain scans and integrates into hospital systems, offering tools for various indications including intracranial hemorrhages and large vessel occlusions. While the product is generally well-regarded for its speed and accuracy in stroke detection, employer reviews indicate significant issues with company culture and management.

Overall: Mixed

Strengths

Expedites triage and transfer decisions for stroke patients.
Accurate detection of intracranial hemorrhage, LVO, and CT perfusion.
Reduces time needed to generate perfusion maps and improves information sharing.
Clinically superior product compared to competitors.
Offers flexibility and customization for hospitals.
Great opportunity for remote work.

Limitations

Toxic sales culture and micromanagement.
Horrible executive team with high turnover and reports of mental abuse.
Mobile app experiences glitches, login issues, and missed notifications.
Uncertain impact on important clinical outcomes like patient harms, mortality, and quality of life due to limited evidence.
Cost-effectiveness for stroke detection is currently unknown.
Product's best value requires a strong stroke service line.

Based on reviews from: Elion, Indeed.com, NCBI Bookshelf, Slashdot, Zippia, Reddit, SoftFinders, Apple App Store, Canadian Journal of Health Technologies, Google Play Store, RapidAI Website

Last updated: 2026-07-18

Videos

News, demos, and interviews about iSchemaview, Inc. (operating as RapidAI).

Loading videos...

Videos load interactively. If none appear, search YouTube for iSchemaview, Inc. (operating as RapidAI) →

View all on YouTube

Press & Coverage

Vista Equity Partners

RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners

RapidAI, a leader in AI and technology workflow solutions for neurovascular, cardiac, and vascular diseases, announced a $75 million Series C funding round led by Vista Credit Partners. This investment aims to fuel platform innovation for new disease states and accelerate growth in new regions and product verticals.

2023-07

MedCity News

RapidAI Rakes In $75M to Accelerate Stroke Diagnosis

RapidAI secured $75 million in Series C funding to advance its AI platform, which assists hospital care teams in rapidly triaging and treating stroke patients. The company's software helps manage high imaging volumes and addresses the critical demand for swift and accurate stroke diagnosis.

2023-07

RapidAI Press Release

RapidAI Receives First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage

RapidAI announced FDA 510(k) clearance for Rapid NCCT Stroke, a non-contrast CT imaging product designed to detect suspected intracranial hemorrhage and large vessel occlusion, marking a significant advancement in acute stroke triage.

2023-04

RapidAI Press Release

RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances

RapidAI received FDA clearance for five new imaging modules: Rapid DeltaFuseu2122, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement, significantly expanding its Rapid Enterpriseu2122 Platform for deep clinical intelligence and workflow integration.

2025-11

RapidAI Press Release

RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts

RapidAI announced 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, highlighting new clinical research on AI-driven gains in aneurysm detection, stroke interpretation, and enterprise imaging efficiency.

2026-02

RapidAI Press Release

RapidAI Receives FDA 510(k) Clearance for Pulmonary Embolism Triage & Notification

RapidAI received FDA 510(k) clearance for its Rapid PE Triage & Notification product, designed for fast identification and communication of suspected central pulmonary embolism, enhancing its clinical AI platform.

2022-05

Stroke: Vascular and Interventional Neurology - American Heart Association Journals

RapidAI Compared With Human Readers of Acute Stroke Imaging for Detection of Intracranial Vessel Occlusion

This article compares the effectiveness of RapidAI with human readers in detecting intracranial vessel occlusion in acute stroke imaging, using LR graphs to assess superiority in ruling in and out occlusion.

2024-01

Canadian Journal of Health Technologies

RapidAI for Stroke Detection and AI Implementation Review

This review examines the implementation of RapidAI for stroke detection as an AI-enabled medical device, serving as a foundational report for evaluating AI technologies in Canada.

2024-11

Frequently Asked Questions

What are RapidAI's core product offerings for neurovascular, cardiac & vascular, and radiology concerns, including ischemic stroke, hemorrhagic stroke, aneurysm, aortic disease, and pulmonary embolism?

RapidAI offers a comprehensive suite of AI-powered solutions through its Rapid Enterprise Platform, addressing neurovascular conditions like ischemic stroke (e.g., Rapid CTP, Rapid LVO, Rapid ASPECTS, Rapid NCCT Stroke, Lumina 3D), hemorrhagic stroke (e.g., Rapid ICH, Rapid Hyperdensity, Rapid ASPECTS), and aneurysms (Rapid Aneurysm). For cardiac and vascular concerns, products like Rapid Aortic and Rapid PE assist with aortic disease and pulmonary embolism. The platform also includes Rapid Navigator Pro to streamline radiology workflows and provide clinical decision support across these diverse areas.

How does RapidAI ensure compliance with healthcare regulations such as HIPAA and FDA, and what certifications do they hold?

RapidAI prioritizes compliance by designing its platform with robust security and data privacy measures, including HIPAA-compliant controls, Business Associate Agreements (BAAs), and data de-identification practices. The company has received multiple FDA clearances for its imaging modules, demonstrating adherence to medical device regulations. Additionally, RapidAI aligns with international standards like ISO 13485 for medical device quality management systems and ISO/IEC 42001 for AI governance.

What is RapidAI's approach to pricing, and how can hospitals integrate it into existing budgets, including potential reimbursement options?

RapidAI's solutions aim to provide significant return on investment (ROI), with reported figures ranging from 3-5x to 10-20x for stroke patients, by improving efficiency, reducing futile transfers, and increasing patient throughput. While specific pricing models are not publicly detailed, the company emphasizes cost-effectiveness through operational and clinical optimization. Certain RapidAI products, such as Rapid LVO, have qualified for New Technology Add-on Payment (NTAP) reimbursement from Medicare, offering additional financial assistance for hospitals adopting these technologies.

What level of support and training does RapidAI provide to healthcare professionals and administrators for implementation and ongoing use?

RapidAI offers comprehensive education and support services, including 24/7 customer support via email and phone, and a dedicated Clinical Learning and Development team. They provide professional education, implementation assistance, and continuous optimization support. Training programs range from self-paced courses to expert-led sessions, designed to equip healthcare professionals with the knowledge and skills to effectively utilize RapidAI products and optimize workflows.

Can you describe RapidAI's key partnerships and how they contribute to care coordination and expanding market reach?

RapidAI collaborates with a global network of technology partners and distributors to enhance its offerings and expand its reach, including companies like Ambra Health, Samsung Neurologica, Mobile Heartbeat, Halo Health, Pulsara, and Siemens Healthineers. Recent strategic partnerships include Saudi Health Holding Company (HHC) for AI-driven healthcare across the Middle East and Amazon Web Services (AWS) to accelerate global deployment and scalability of its AI solutions. These partnerships facilitate seamless integration, improved care coordination, and broader access to RapidAI's technology.

How does RapidAI address workflow optimization and clinical decision support specifically within radiology and across the enterprise?

RapidAI's Rapid Enterprise Platform and Rapid Navigator Pro are designed to optimize radiology workflows by integrating directly with PACS, EHRs, worklists, and reporting systems. The platform provides deep clinical AI that goes beyond detection to offer contextual insights, automate tasks like structured reporting, prioritize critical findings, and reduce cognitive burden for radiologists. This streamlines image analysis, accelerates clinical decision-making, and enhances care coordination across various departments.

What is RapidAI's company stability and long-term viability, given its role in critical care areas?

RapidAI demonstrates strong company stability and long-term viability as a global leader and pioneer in Deep Clinical AI, with its platform used in over 2,500 hospitals across more than 100 countries. The company is backed by over 700 clinical studies, including research that influenced national stroke treatment guidelines. Its continuous innovation, strategic acquisitions like EndoVantage, and expanding enterprise deployments, supported by partnerships with major technology providers like AWS, underscore its commitment to advancing patient care across multiple disease states.

Related Companies

Suggest an Edit →